Question 1

What is congenital disorder of deglycosylation 2?

Accepted Answer

Congenital disorder of deglycosylation 2 is a multisystem condition that primarily affects early neurodevelopment and overall growth. It is associated with a range of neurological findings including motor delay, delayed speech, and intellectual disability as well as various structural brain abnormalities. Genetic variants in the MAN2C1 gene underlie this condition, and it typically presents in childhood. Because precise prevalence estimates are not established, the disorder is considered a very rare condition with variable clinical presentation.

Question 2

What are the symptoms of congenital disorder of deglycosylation 2?

Accepted Answer

The clinical features of congenital disorder of deglycosylation 2 are diverse and affect multiple organ systems. Neurologically, affected children often experience motor delay, delayed speech and language development, and a degree of intellectual disability that can impact learning and social interactions. Brain imaging frequently reveals abnormalities such as cerebellar vermis hypoplasia, ventriculomegaly, polymicrogyria, and partial agenesis of the corpus callosum. In addition, some individuals exhibit facial dysmorphisms including micrognathia, short columella, a highly arched eyebrow, and a high forehead, along with other features such as microtia and a hamartoma of the tongue. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes congenital disorder of deglycosylation 2?

Accepted Answer

Congenital disorder of deglycosylation 2 is caused by pathogenic variants in the MAN2C1 gene. Although the detailed molecular mechanism has not been fully elucidated in the provided information, MAN2C1 is implicated in the process of deglycosylation, which is important for normal protein processing and cellular function. The condition is inherited in an autosomal recessive pattern, meaning that affected individuals have two copies of the altered gene, one inherited from each parent. This pattern also suggests that the disorder is more likely to occur when both parents share a common ancestral background. Associated genes include MAN2C1.

Question 4

How is congenital disorder of deglycosylation 2 inherited?

Accepted Answer

congenital disorder of deglycosylation 2 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How is congenital disorder of deglycosylation 2 diagnosed?

Accepted Answer

The diagnosis of congenital disorder of deglycosylation 2 is confirmed through molecular genetic testing, which identifies pathogenic variants in the MAN2C1 gene. A comprehensive clinical evaluation that includes assessment of developmental history, neuroimaging findings, and physical examination for characteristic craniofacial and musculoskeletal features is essential. Although the symptoms can overlap with other conditions, genetic testing is key to providing a definitive diagnosis.

Question 6

Are there treatments for congenital disorder of deglycosylation 2?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as no treatments have been specifically approved for congenital disorder of deglycosylation 2. A multidisciplinary team typically oversees care, with interventions that may include physical and speech therapy, educational support, and other tailored strategies to address individual needs. In addition to treating active symptoms, regular surveillance is an essential part of long-term management to identify potential complications early. Genetic counseling is recommended to help families understand inheritance patterns and assist with future family planning.

Question 7

Are there clinical trials for congenital disorder of deglycosylation 2?

Accepted Answer

Yes, there is currently 1 active clinical trial for congenital disorder of deglycosylation 2 registered on ClinicalTrials.gov. Clinical trials test new treatments, procedures, or approaches. Your healthcare provider can help determine if a trial might be appropriate for your situation. Visit the Treatment section of this page for more details.

Question 8

What are the specific neurological findings associated with congenital disorder of deglycosylation 2?

Accepted Answer

Congenital disorder of deglycosylation 2 is linked to various neurological findings. Affected children often experience motor delay, delayed speech and language development, and intellectual disability. Brain imaging may show abnormalities like cerebellar vermis hypoplasia and polymicrogyria, which can affect their overall development and learning.

Question 9

How does congenital disorder of deglycosylation 2 affect daily life and development?

Accepted Answer

Congenital disorder of deglycosylation 2 can significantly impact daily life and development. Children may face challenges with motor skills, speech, and social interactions due to their developmental delays. Supportive care, including physical and speech therapy, can help improve their abilities and enhance their quality of life.

Question 10

What is the long-term prognosis for someone with congenital disorder of deglycosylation 2?

Accepted Answer

The long-term prognosis for individuals with congenital disorder of deglycosylation 2 varies widely. Many affected individuals can develop and achieve different levels of independence with supportive care. Although there may be initial developmental delays, some patients experience periods of stabilization and improvement over time.

Question 11

What kind of specialists should families consult for congenital disorder of deglycosylation 2?

Accepted Answer

Families dealing with congenital disorder of deglycosylation 2 should consult a multidisciplinary team of specialists. This may include neurologists, geneticists, and therapists who can provide tailored support and interventions. Regular follow-ups with these specialists are essential for monitoring development and addressing any emerging needs.

Organ System	Phenotype Count	Example Features
Head and neck	4	Cleft earlobe, High palate, Macrocephaly

Kisho

congenital disorder of deglycosylation 2

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Latest News & Developments

FDA Grants Breakthrough Therapy Designation to Glycomine’s GLM101 for the Treatment of PMM2-CDG - BioSpace

congenital disorder of deglycosylation 2

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is congenital disorder of deglycosylation 2?

What are the symptoms of congenital disorder of deglycosylation 2?

What causes congenital disorder of deglycosylation 2?

How is congenital disorder of deglycosylation 2 inherited?

How is congenital disorder of deglycosylation 2 diagnosed?

Are there treatments for congenital disorder of deglycosylation 2?

Are there clinical trials for congenital disorder of deglycosylation 2?

What are the specific neurological findings associated with congenital disorder of deglycosylation 2?

How does congenital disorder of deglycosylation 2 affect daily life and development?

What is the long-term prognosis for someone with congenital disorder of deglycosylation 2?

What kind of specialists should families consult for congenital disorder of deglycosylation 2?

Explore clinical features

Latest News & Developments

FDA Grants Breakthrough Therapy Designation to Glycomine’s GLM101 for the Treatment of PMM2-CDG - BioSpace